Everpar Advisors LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Everpar Advisors LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 4,014 shares of the medical research company’s stock, valued at approximately $1,156,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Gryphon Financial Partners LLC lifted its holdings in shares of Amgen by 295.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock worth $1,021,000 after acquiring an additional 2,752 shares during the last quarter. Moss Adams Wealth Advisors LLC acquired a new stake in Amgen in the fourth quarter valued at approximately $588,000. Pacific Capital Wealth Advisors Inc. acquired a new position in shares of Amgen during the fourth quarter worth $198,000. Barlow Wealth Partners Inc. bought a new position in shares of Amgen in the 4th quarter valued at $2,270,000. Finally, Patrick M Sweeney & Associates Inc. bought a new stake in Amgen during the 4th quarter worth $266,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 2.3 %

AMGN stock traded up $7.01 during midday trading on Wednesday, reaching $307.31. 2,858,665 shares of the company’s stock traded hands, compared to its average volume of 2,909,728. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The firm’s fifty day moving average price is $275.65 and its 200-day moving average price is $281.74. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a market cap of $164.85 billion, a price-to-earnings ratio of 43.90, a P/E/G ratio of 3.00 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. During the same period in the prior year, the business posted $3.98 earnings per share. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 128.57%.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price target on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. TD Cowen reduced their price objective on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. BMO Capital Markets raised their target price on Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $305.05.

Insider Buying and Selling

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.